Development of humanized antibodies as cancer therapeutics.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Methods

• Publication date

  2005-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.YMETH.2005.01.008PMID 15848077
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy.

  2005cited by this paper
• Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.

  2004cited by this paper
• Preclinical Therapy of Breast Cancer with a Radioiodinated Humanized Anti-EGP-1 Monoclonal Antibody: Advantage of a Residualizing Iodine Radiolabel

  2004cited by this paper
• Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.

  2004cited by this paper
• Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma

  2004cited by this paper
• Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma

  2004cited by this paper
• 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.

  2003cited by this paper
• Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.

  2003cited by this paper
• Improved iodine radiolabels for monoclonal antibody therapy.

  2003cited by this paper
• A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.

  2003cited by this paper
• 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

  2003cited by this paper
• Renaissance of cancer therapeutic antibodies.

  2003cited by this paper
• Myeloma expression systems.

  2002cited by this paper
• Molecular Cloning: A Laboratory Manual

  2001cited by this paper
• Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.

  2001cited by this paper
• Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.

  1999cited by this paper
• Humanization of Immu31, an alpha-fetoprotein-specific antibody.

  1999cited by this paper
• Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.

  1999cited by this paper
• Generation and monitoring of cell lines producing humanized antibodies.

  1999cited by this paper
• Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids.

  1999cited by this paper
• Signaling antibodies in cancer therapy.

  1999cited by this paper
• Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.

  1999cited by this paper
• CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor.

  1998cited by this paper
• Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.

  1998cited by this paper
• 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.

  1998cited by this paper
• Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

  1997cited by this paper
• Chimerization of mu‐9

  1997cited by this paper
• Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22

  1997cited by this paper
• Generation of a high‐producing clone of a humanized anti‐B‐cell lymphoma monoclonal antibody (hLL2)

  1997cited by this paper
• The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma.

  1996cited by this paper
• Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.

  1995cited by this paper
• Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.

  1995cited by this paper
• Murine and humanized constructs of monoclonal antibody m195 (anti‐cd33) for the therapy of acute myelogenous leukemia

  1994cited by this paper
• Chimerization of LL2, a Rapidly Internalizing Antibody Specific for B Cell Lymphoma

  1994cited by this paper
• Cancer Therapy with Radiolabeled Antibodies

  1994cited by this paper
• An extended primer set for PCR amplification of murine kappa variable regions.

  1993cited by this paper
• The coming of age of cancer radioimmunoconjugates.

  1993cited by this paper
• Radiohalogenation of proteins: An overview of radionuclides, labeling methods and reagents for conjugate labeling

  1992cited by this paper
• “Primatization” of Recombinant Antibodies for Immunotherapy of Human Diseases: A Macaque/Human Chimeric Antibody Against Human CD4

  1992cited by this paper
• Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling.

  1992cited by this paper
• Antibody engineering : a practical guide

  1992cited by this paper
• Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells.

  1992cited by this paper
• Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo

  1991cited by this paper
• High-level expression of chimeric antibodies using adapted cDNA variable region cassettes.

  1989cited by this paper
• Modeling antibody hypervariable loops: a combined algorithm.

  1989cited by this paper
• Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.

  1989cited by this paper
• Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications.

  1989cited by this paper
• Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity.

  1989cited by this paper
• Reshaping human antibodies: grafting an antilysozyme activity.

  1988cited by this paper
• Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer.

  1988cited by this paper
• Complete variable region sequence of a nonfunctionally rearranged kappa light chain transcribed in the nonsecretor P3-X63-Ag8.653 myeloma cell line.

  1987cited by this paper
• Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression.

  1986cited by this paper
• Modelling of the combining sites of three anti‐lysozyme monoclonal antibodies and of the complex between one of the antibodies and its epitope.

  1986cited by this paper
• Human immune response to multiple injections of murine monoclonal IgG.

  1985cited by this paper
• Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma.

  1984cited by this paper
• Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

  1984cited by this paper
• Quantitative analysis of cell surface HLA structures by means of monoclonal antibodies.

  1980cited by this paper
• THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

  1963cited by this paper
• Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity

  1962cited by this paper

• Nanotechnology Approaches for Mitigating Biologic Immunogenicity: A Literature Review

  2025cites this paper
• Qualitative analysis and controllability of complex tumor model with different therapies with nonsingular kernel

  2025cites this paper
• Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis

  2025cites this paper
• Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy.

  2023cites this paper
• Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective

  2022cites this paper
• Trastuzumab immunogenicity development in patients’ sera and in laboratory animals

  2021cites this paper
• Preparation, Characterization and Diagnostic Valuation of Two Novel Anti-HPV16 E7 Oncoprotein Monoclonal Antibodies

  2020cites this paper
• EPB41L5 Mediates TGFβ-Induced Metastasis of Gastric Cancer

  2019cites this paper
• Therapeutic Antibody Case Study: Humanized Xolair

  2014influential citation
• Multimodal therapy for complete regression of malignant melanoma using constrained nonlinear optimal dynamic inversion

  2014cites this paper
• Abstract A53: Metadherin functions as a laminin receptor that is essential for metastasis and is associated with poor survival in osteosarcoma

  2014cites this paper
• Modeling Tumor–Immune Dynamics

  2014cites this paper
• Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer

  2014cites this paper
• Conjugation of anti-CD 47 antibody to gold nanoparticles via click chemistry for cancer therapy

  2014influential citation
• SM 5-1-Conjugated PLA nanoparticles loaded with 5-fl uorouracil for targeted hepatocellular carcinoma imaging and therapy

  2014cites this paper
• Large Molecule Therapeutics Rationale and Preclinical Ef fi cacy of a Novel Anti-EMP 2 Antibody for the Treatment of Invasive Breast Cancer

  2014cites this paper
• SM5-1-conjugated PLA nanoparticles loaded with 5-fluorouracil for targeted hepatocellular carcinoma imaging and therapy.

  2014cites this paper
• Impact of Product Attributes on Preclinical Safety Evaluation

  2013cites this paper
• 22. ImmunoRNase Fusions

  2013cites this paper
• Rationale and pre-clinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer

  2013cites this paper
• Chemical and Genetic Modification

  2013cites this paper
• Evaluation of a Novel Hexavalent Humanized Anti-IGF-1R Antibody and Its Bivalent Parental IgG in Diverse Cancer Cell Lines

  2012cites this paper
• Antibodies for Nuclear Medicine Therapy

  2012cites this paper
• Targeted Therapy in Hematologic Malignancies

  2011cites this paper
• Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding

  2011cites this paper
• Design and Application of Immunoconjugates for Cancer Therapy

  2011cites this paper
• A new mammalian host cell with enhanced survival enables completely serum‐free development of high‐level protein production cell lines

  2011cites this paper
• Inhibiteurs de tyrosine kinase utilisés dans les tumeurs solides : proposition de fiches d'utilisation pratique destinées à l'équipe officinale

  2011cites this paper
• The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment

  2010cites this paper
• Pulmonary toxicities of biologics: a review

  2010cites this paper
• RNA as performance-enhancers for dendritic cells

  2010cites this paper
• linical Development pirnase ( Frog RNase ) Targeted with a Humanized , rnalizing , Anti – Trop-2 Antibody Has Potent Cytotoxicity Ther inst Diverse Epithelial Cancer Cells

  2010cites this paper
• Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells

  2010cites this paper
• R&D Paradigm Shift and Billion‐Dollar Biologics

  2010cites this paper
• Targeted Therapies in Cancer

  2010cites this paper
• A fatal case of alemtuzumab-associated interstitial pneumonitis.

  2008cites this paper
• Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.

  2008cites this paper
• Development of monoclonal antibodies for the identification of novel invasion associated targets in human cancer.

  2008cites this paper
• Production systems for recombinant antibodies.

  2008cites this paper
• In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies

  2008cites this paper
• Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review.

  2008cites this paper
• Serum soluble interleukin 2 receptor α in human cancer of adults and children: a review

  2008influential citation
• Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells.

  2008cites this paper
• Biological evaluation of 153Sm and 166Ho complexes with tetraazamacrocycles containing methylcarboxylate and/or methylphosphonate pendant arms

  2007cites this paper
• Radiolanthanides / Tetraazamacrocycles / Phosphonates / Carboxylates / Biodistribution / Therapy

  2007cites this paper
• Immunization with Mimotopes Prevents Growth of Carcinoembryonic Antigen–Positive Tumors in BALB/c Mice

  2007cites this paper
• Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy

  2007cites this paper
• Update: Recombinant Antibodies: From the Laboratory to the Clinic

  2006cites this paper
• Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations.

  2006cites this paper
• Adverse effects of the humanized antibodies used as cancer therapeutics

  2006cites this paper
• Development of human-human hybridoma from anti-Her-2 peptide-producing B cells in immunized NOG mouse.

  2006cites this paper
• Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates

  2006cites this paper
• Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer.

  2006cites this paper
• Advances in Radioimmunotherapy in the Age of Molecular Engineering and Pretargeting

  2006cites this paper
• High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells1

  2006cites this paper
• A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration.

  2006cites this paper
• Selective delivery of therapeutic agents for the diagnosis and treatment of cancer

  2006cites this paper
• Optimizing the affinity and specificity of proteins with molecular display.

  2006cites this paper
• Different strategies for cancer treatment: Mathematical modelling

  2006cites this paper
• Selection, design, and engineering of therapeutic antibodies.

  2005cites this paper
• Anticorps humanisés en thérapeutique

  2005cites this paper
• Anticorps­ en­thérapeutique

  2005cites this paper
• Molecular mechanisms in allergy and clinical immunology

  2005cites this paper
• [Humanized antibodies as therapeutics].

  2005cites this paper
• Title : Mixed Immunotherapy and Chemotherapy of Tumors : Modeling , Applications and Biological Interpretations

  2005cites this paper